PL3268356T3 - Związki heterocykliczne i sposoby ich stosowania - Google Patents
Związki heterocykliczne i sposoby ich stosowaniaInfo
- Publication number
- PL3268356T3 PL3268356T3 PL16715616T PL16715616T PL3268356T3 PL 3268356 T3 PL3268356 T3 PL 3268356T3 PL 16715616 T PL16715616 T PL 16715616T PL 16715616 T PL16715616 T PL 16715616T PL 3268356 T3 PL3268356 T3 PL 3268356T3
- Authority
- PL
- Poland
- Prior art keywords
- methods
- heterocyclic compounds
- heterocyclic
- compounds
- Prior art date
Links
- 150000002391 heterocyclic compounds Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2015900878A AU2015900878A0 (en) | 2015-03-12 | Heterocyclic compounds and methods for their use | |
| AU2015902830A AU2015902830A0 (en) | 2015-07-17 | Heterocyclic compounds and methods for their use | |
| PCT/IB2016/051318 WO2016142867A1 (en) | 2015-03-12 | 2016-03-09 | Heterocyclic compounds and methods for their use |
| EP16715616.5A EP3268356B1 (en) | 2015-03-12 | 2016-03-09 | Heterocyclic compounds and methods for their use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3268356T3 true PL3268356T3 (pl) | 2022-01-24 |
Family
ID=60544648
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL16715616T PL3268356T3 (pl) | 2015-03-12 | 2016-03-09 | Związki heterocykliczne i sposoby ich stosowania |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US10308628B2 (pl) |
| EP (1) | EP3268356B1 (pl) |
| JP (1) | JP6826993B2 (pl) |
| CN (1) | CN107466293B (pl) |
| ES (1) | ES2898635T3 (pl) |
| PL (1) | PL3268356T3 (pl) |
| PT (1) | PT3268356T (pl) |
| WO (1) | WO2016142867A1 (pl) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3245198T (pt) | 2015-01-13 | 2020-06-16 | Novartis Ag | Derivados de pirrolidina como antagonistas de angiotensina ii tipo 2 |
| NZ750781A (en) | 2016-09-09 | 2025-06-27 | Novartis Ag | Compounds and compositions as inhibitors of endosomal toll-like receptors |
| WO2024182271A1 (en) * | 2023-02-27 | 2024-09-06 | Enanta Pharmaceuticals, Inc. | Fused heterotetracyclic antiviral agents |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1451173A4 (en) | 2001-11-01 | 2005-10-26 | Icagen Inc | PIPERIDINE |
| WO2006066361A1 (en) | 2004-12-24 | 2006-06-29 | The University Of Queensland | Method of treatment or prophylaxis |
| JP5230595B2 (ja) | 2006-03-20 | 2013-07-10 | スピニフェクス ファーマシューティカルズ ピーティーワイ リミテッド | 炎症性疼痛の治療または予防の方法 |
| US9095587B2 (en) | 2010-01-19 | 2015-08-04 | Spinifex Pharmaceuticals Pty Ltd | Methods and compositions for improved nerve conduction velocity |
| PL2595960T3 (pl) | 2010-07-21 | 2016-09-30 | Sól i solwaty pochodnej tetrahydroizochinoliny | |
| ES2802251T3 (es) | 2012-01-06 | 2021-01-18 | Novartis Ag | Compuestos heterocíclicos y métodos para su uso |
| EP2807171B1 (en) * | 2012-01-25 | 2020-08-12 | Novartis AG | Heterocyclic compounds and methods for their use |
| PT2807153T (pt) | 2012-01-25 | 2020-06-18 | Novartis Ag | Compostos heterocíclicos e métodos para seu uso |
| WO2015003223A1 (en) * | 2013-07-08 | 2015-01-15 | Spinifex Pharmaceuticals Pty Ltd | Heterocyclic compounds and methods of their use |
| PT3245198T (pt) | 2015-01-13 | 2020-06-16 | Novartis Ag | Derivados de pirrolidina como antagonistas de angiotensina ii tipo 2 |
-
2016
- 2016-03-09 US US15/556,593 patent/US10308628B2/en active Active
- 2016-03-09 WO PCT/IB2016/051318 patent/WO2016142867A1/en not_active Ceased
- 2016-03-09 EP EP16715616.5A patent/EP3268356B1/en active Active
- 2016-03-09 CN CN201680019027.2A patent/CN107466293B/zh active Active
- 2016-03-09 ES ES16715616T patent/ES2898635T3/es active Active
- 2016-03-09 PL PL16715616T patent/PL3268356T3/pl unknown
- 2016-03-09 JP JP2017548066A patent/JP6826993B2/ja active Active
- 2016-03-09 PT PT167156165T patent/PT3268356T/pt unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2898635T3 (es) | 2022-03-08 |
| JP6826993B2 (ja) | 2021-02-10 |
| EP3268356B1 (en) | 2021-08-25 |
| CN107466293B (zh) | 2020-09-11 |
| US20180057477A1 (en) | 2018-03-01 |
| PT3268356T (pt) | 2021-11-23 |
| US10308628B2 (en) | 2019-06-04 |
| JP2018507897A (ja) | 2018-03-22 |
| EP3268356A1 (en) | 2018-01-17 |
| CN107466293A (zh) | 2017-12-12 |
| WO2016142867A1 (en) | 2016-09-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL258180B (en) | Heterocyclic compounds and their uses | |
| ZA201804070B (en) | Eif4-a-inhibiting compounds and methods related thereto | |
| IL258768A (en) | Compounds interacting with glycans and methods of use | |
| SG11201605417QA (en) | Heterocyclic compounds | |
| SI3215147T1 (sl) | Nevroatenuacijske spojine norketamina in postopki | |
| IL252560B (en) | Heterocyclic derivatives and their uses | |
| IL247018A0 (en) | Heterocyclic compound | |
| IL246140B (en) | History of bicyclic heterocyclics as bromodomain repressors | |
| IL285105A (en) | Heterocyclic compound | |
| SG11201708027XA (en) | Compounds and their use as bace1 inhibitors | |
| IL251107A0 (en) | Compounds and methods | |
| GB201608779D0 (en) | Methods and compounds | |
| EP3197885A4 (en) | Heterocyclic compounds and use thereof | |
| IL247325A0 (en) | Therapeutic methods using noribogaine and related compounds | |
| GB201608776D0 (en) | Methods and compounds | |
| PL3268356T3 (pl) | Związki heterocykliczne i sposoby ich stosowania | |
| GB201416351D0 (en) | Heterocyclic derivatives | |
| AU2015903010A0 (en) | Heterocyclic Compounds and Methods for their Use | |
| AU2015902922A0 (en) | Heterocyclic compounds and methods for their use | |
| AU2015902886A0 (en) | Heterocyclic Compounds And Methods For Their Use | |
| AU2015902830A0 (en) | Heterocyclic compounds and methods for their use | |
| AU2015901751A0 (en) | Heterocyclic Compounds And Methods For Their Use | |
| AU2015900878A0 (en) | Heterocyclic compounds and methods for their use | |
| AU2015900077A0 (en) | Heterocyclic compounds and methods for their use | |
| GB201514770D0 (en) | Compounds and their use |